TY - JOUR
T1 - Glymphotherapeutics for Alzheimer's disease
T2 - Time to move the needle
AU - MohanaSundaram, Arun Sundar
AU - Mofatteh, Mohammad
AU - Ashraf, Ghulam Md
AU - Praticò, Domenico
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/11
Y1 - 2024/11
N2 - Alzheimer's disease (AD), the most predominant neurodegenerative disease and a quintessential entity within the dementia umbrella, is a global public health crisis. While the lack of disease modifying therapies has been a weak point in AD treatment, the success of recently approved monoclonal antibody-based therapeutics (aducanumab and lecanemab) targeted at the removal of amyloid-beta (Aβ) peptides in the brain is still under debate. There are multiple safety concerns about these approved neurotherapeutics including amyloid-related imaging abnormalities, stroke, meningitis, encephalitis, and even death. Novel paradigms focused on aquaporin-4-mediated neuro-perivascular Aβ and Tau protein clearance pathway are garnering attention. In this paper, we argue that orchestrating the drug discovery focused on glymphatic clearance-facilitating drugs (“glymphotherapeutics”) might be a potentially novel and viable strategy to mitigate the progression and improve the clinical outcomes of AD.
AB - Alzheimer's disease (AD), the most predominant neurodegenerative disease and a quintessential entity within the dementia umbrella, is a global public health crisis. While the lack of disease modifying therapies has been a weak point in AD treatment, the success of recently approved monoclonal antibody-based therapeutics (aducanumab and lecanemab) targeted at the removal of amyloid-beta (Aβ) peptides in the brain is still under debate. There are multiple safety concerns about these approved neurotherapeutics including amyloid-related imaging abnormalities, stroke, meningitis, encephalitis, and even death. Novel paradigms focused on aquaporin-4-mediated neuro-perivascular Aβ and Tau protein clearance pathway are garnering attention. In this paper, we argue that orchestrating the drug discovery focused on glymphatic clearance-facilitating drugs (“glymphotherapeutics”) might be a potentially novel and viable strategy to mitigate the progression and improve the clinical outcomes of AD.
KW - Alzheimer's disease
KW - Aquaporin-4
KW - Dementia
KW - Glymphatic clearance
KW - Glymphotherapeutics
KW - Neurodegenerative disease
KW - Neurotherapeutics
UR - http://www.scopus.com/inward/record.url?scp=85203287678&partnerID=8YFLogxK
U2 - 10.1016/j.arr.2024.102478
DO - 10.1016/j.arr.2024.102478
M3 - Review article
C2 - 39222666
AN - SCOPUS:85203287678
SN - 1568-1637
VL - 101
JO - Ageing Research Reviews
JF - Ageing Research Reviews
M1 - 102478
ER -